Results 1 to 10 of about 25,256 (244)
Some of the next articles are maybe not open access.
CNS Drugs, 1997
[Symbol: see text] Levetiracetam is an ethyl analogue of the nootropic agent piracetam.[Symbol: see text] Results from rodent studies indicate that the drug may offer protection against absence, generalised and partial seizures.[Symbol: see text] Levetiracetam exhibits linear pharmacokinetics and has a wide therapeutic index.
M, Haria, J A, Balfour
openaire +2 more sources
[Symbol: see text] Levetiracetam is an ethyl analogue of the nootropic agent piracetam.[Symbol: see text] Results from rodent studies indicate that the drug may offer protection against absence, generalised and partial seizures.[Symbol: see text] Levetiracetam exhibits linear pharmacokinetics and has a wide therapeutic index.
M, Haria, J A, Balfour
openaire +2 more sources
Reactions Weekly, 2019
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes.
+5 more sources
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes.
+5 more sources
American Journal of Health-System Pharmacy, 2001
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of levetiracetam are reviewed. Levetiracetam is an adjunctive treatment for partial-onset epileptic seizures. This drug inhibits seizure activity via a mechanism that does not involve excitatory or inhibitory neuronal pathways.
E M, Nash, K S, Sangha
openaire +2 more sources
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of levetiracetam are reviewed. Levetiracetam is an adjunctive treatment for partial-onset epileptic seizures. This drug inhibits seizure activity via a mechanism that does not involve excitatory or inhibitory neuronal pathways.
E M, Nash, K S, Sangha
openaire +2 more sources
Expert Opinion on Drug Safety, 2007
Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged > or = 12 years with juvenile myoclonic epilepsy.
Deepa, Sirsi, Joseph E, Safdieh
openaire +2 more sources
Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged > or = 12 years with juvenile myoclonic epilepsy.
Deepa, Sirsi, Joseph E, Safdieh
openaire +2 more sources
Levetiracetam in Tardive Dyskinesia
Clinical Neuropharmacology, 2006The aim of this study was to evaluate the effect of levetiracetam on tardive dyskinesia (TD), which is known to be a major limitation of chronic antipsychotic drug therapy, particularly with conventional antipsychotics.Sixteen patients suffering from chronic psychosis with TD were enrolled consecutively.
MECO G +7 more
openaire +4 more sources
Drugs of Today, 2007
Levetiracetam (LEV) is a broad-spectrum antiepileptic drug that is effective against a variety of seizure types. It is a pyrridoline derivative with a very favourable pharmacokinetic profile: excellent bioavailability, linear kinetics, minimal plasma protein binding and quick achievement of steady state concentrations. It is not metabolized through the
openaire +2 more sources
Levetiracetam (LEV) is a broad-spectrum antiepileptic drug that is effective against a variety of seizure types. It is a pyrridoline derivative with a very favourable pharmacokinetic profile: excellent bioavailability, linear kinetics, minimal plasma protein binding and quick achievement of steady state concentrations. It is not metabolized through the
openaire +2 more sources
Pharmacokinetics of Levetiracetam
Epilepsia, 2001Summary: Major considerations in the acceptance and impact of new antiepileptic drugs include their pharmacokinetics and their potential for interaction with other drugs. The pharmacokinetics of levetiracetam, a newly approved add‐on antiepileptic agent for partial‐onset seizures in adults, has been evaluated in 27 phase I and II studies.
openaire +2 more sources
Levetiracetam in Childhood Epilepsy
Pediatric Drugs, 2010Levetiracetam is an antiepileptic drug that has been shown to be effective in various types of seizures, both partial and generalized. Although it is not yet well established because of the small number of studies, levetiracetam as both add-on therapy and monotherapy can be considered as an alternative to valproic acid in some pediatric patients.
VERROTTI DI PIANELLA, Alberto +4 more
openaire +2 more sources